TIR50
$429.99
0 Reviews
50MG Tirzepatide. Two-week delivery time frame for this product.
Product Overview:
Tirzepatide is a novel, once-weekly subcutaneous injectable medication designed to support glycemic control and weight management in individuals with type 2 diabetes and/or obesity. As a dual incretin agonist, Tirzepatide activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, offering a synergistic mechanism that enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
Key Features:
-
Dual Receptor Activation: Targets both GLP-1 and GIP pathways for enhanced glucose regulation and weight reduction.
-
Improved Glycemic Control: Demonstrated significant A1C reduction in clinical trials.
-
Weight Loss Support: Clinically proven to reduce body weight in individuals with obesity or overweight, with or without diabetes.
-
Convenient Dosing: Once-weekly subcutaneous injection for improved adherence and patient convenience.
-
Cardiometabolic Benefits: Potential improvements in cardiovascular risk factors, pending further study.
Available on backorder
Description
Mechanism of Action:
Tirzepatide binds to and activates both GLP-1 and GIP receptors, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, delaying gastric emptying, and increasing satiety—leading to better glycemic control and sustained weight loss.
Important Safety Information:
-
Contraindications: Personal or family history of medullary thyroid carcinoma (MTC), patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or hypersensitivity to Tirzepatide.
-
Warnings: Risk of thyroid C-cell tumors, pancreatitis, gastrointestinal adverse reactions, hypoglycemia (especially when used with insulin or sulfonylureas), and renal impairment.
-
Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus.
RESEARCH PURPOSES ONLY!




